# CollPlant

an Israeli-European player producing highly pure recombinant human collagen (rhCollagen) as a premium foundation for commercial bioinks.

Source: https://en.bioecon.ru/companies/collplant/
Updated: 2026-06-24

- Country: Israel
- Ticker: CLPT

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Approximately $2.3 million in net proceeds from a private placement of ordinary shares and warrants. (2026-07-06) | https://www.sec.gov/Archives/edgar/data/1631487/000121390026076733/ea0297371-f3_collplant.htm |
| Certification | ISO13485:2016 certification and DEKRA (European Union Notified Body) certification for the manufacturing and purification of rhCollagen at its Rehovot facility. (2019-02-19) | https://ir.collplant.com/news-events/press-releases/detail/61/collplant-announces-approval-of-its-rhcollagen-manufacturing-facility-by-european-union-notified-body |
| Production site | A 6,000 square foot production facility in Rehovot, Israel, designed for purification of rhCollagen and formulation of end-products. (2019-02-19) | https://ir.collplant.com/news-events/press-releases/detail/61/collplant-announces-approval-of-its-rhcollagen-manufacturing-facility-by-european-union-notified-body |
| Headcount | Reduced by approximately 50% as part of a cost-cutting plan announced in April 2026. (2026-04-13) | https://everyticker.com/quote/CLGN/news/collplant-biotechnologies-terminates-abbvie-development-agreement-announces-50-workforce-cut-amid-na, https://ir.collplant.com/news-events/press-releases/detail/200/collplant-biotechnologies-reports-2026-first-quarter-financial-results-and-provides-corporate-update, https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-d216415ba7c4.html |
| Revenue | $73,000 for the first quarter of 2026. (2026-03-31) | https://www.prnewswire.com/il/news-releases/collplant-biotechnologies-reports-2026-first-quarter-financial-results-and-provides-corporate-update-302785500.html, https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-d216415ba7c4.html |
| Capacity | The company has experience manufacturing limited quantities of rhCollagen and is working to increase its commercial-scale production capacity. Its Rehovot facility includes equipment to support production demand for several years. [medium confidence] | https://ir.collplant.com/news-events/press-releases/detail/61/collplant-announces-approval-of-its-rhcollagen-manufacturing-facility-by-european-union-notified-body, https://ir.collplant.com/sec-filings/all-sec-filings/content/0001213900-26-034393/ea0282912-20f_collplant.htm |

Independent sources: everyticker.com, prnewswire.com, sec.gov, stocktitan.net

## Technologies

- [Organ & tissue bioprinting](https://en.bioecon.ru/technology/organ-tissue-bioprinting/)
- [Recombinant collagen & gelatin](https://en.bioecon.ru/technology/recombinant-collagen-gelatin/)